fimasartan and Carotid-Artery-Diseases

The renin-angiotensin system plays an important role in promoting atherosclerotic plaque inflammation, which may be inhibited by angiotension-II receptor blockers.. We investigated the effects of fimasartan and amlodipine therapy on carotid atherosclerotic plaque inflammation using. Fifty patients with acute coronary syndrome (ACS) and at least one lesion with. The two groups had similar baseline characteristics. At the 6-month follow-up, index vessel and aorta MDS TBR significantly decreased in both groups. However, the percent change in index vessel MDS TBR was similar between the two groups (-9.33 ± 14.2% vs -7.73 ± 19.1%, respectively, P = 0.9). No significant difference was found for the percent change in the whole vessel TBR for the index vessel between the two groups, with similar findings for changes in MDS TBR or whole vessel TBR for the aorta. Total cholesterol, low-density lipoprotein cholesterol levels, and blood pressure improved to a similar degree in both groups.. Fimasartan and amlodipine reduce carotid atherosclerotic plaque inflammation similarly in patients with ACS, offering the same level of effectiveness.

Topics: Amlodipine; Biphenyl Compounds; Calcium Channel Blockers; Carotid Arteries; Carotid Artery Diseases; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Inflammation; Male; Middle Aged; Plaque, Atherosclerotic; Positron-Emission Tomography; Prospective Studies; Pyrimidines; Tetrazoles; Treatment Outcome